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PanleukopeniaThe results of four challenge studies following co-administration of cats with a trivalent vaccine (feline
calicivirus, feline herpes virus and feline panleukopenia virus; Versifel CVR) and feline leukaemia virus vac-
cine (Versifel FeLV) are described. Nine week old cats received two vaccinations, 21 days apart, adminis-
tered concurrently (two vaccinations) or simultaneously (single vaccination) while non-vaccinated
control cats received sterile water. Three weeks after the second dose all cats were challenged; clinical
observations, rectal or tympanic temperatures and blood samples were collected throughout the study.
In all studies tympanic temperatures remainednormal throughout the study. In theFeLVstudymild, tran-
sient local reactions were seen in vaccinated cats. Following challenge, persistent antigenaemia was
detected in 10/11 (91%) of non-vaccinated cats compared to 4/16 (25%) concurrent and 3/15 (20%) simulta-
neous vaccinated cats. Following challenge with FHV, cats in all groups showed abnormal clinical signs;
however, there were signiﬁcant differences in clinical scores between both the vaccinated groups and the
non-vaccinated group. Antibody responses to FHV in vaccinated and non-vaccinated cats showed a rapid
increase following challenge. Following challenge with FPV no abnormal clinical observations were seen
in any of the treatment groups. All (6/6) non-vaccinated cats demonstrated a greater than 50% reduction
inwhiteblood cells counts, andalso showeda reduction in lymphocyte andneutrophil counts. Twoof 6 con-
currently vaccinated cats also had a greater than 50% reduction in neutrophil counts and another cat (1/6)
had similar reductions in monocytes. The antibody responses to FPV following vaccination increased rap-
idly, peaking prior to second vaccination and remaining stable thereafter; non-vaccinated cats sero-con-
verted following challenge. Following challenge with FCV, non-vaccinated cats had a high incidence of
ulcers, with two to three vaccinated cats also observed with this clinical sign. However, there were highly
signiﬁcant (P < 0.0001) differences between both vaccinated treatment and the non-vaccinated groups in
clinical scores. The antibody responses to FCV in vaccinated and non-vaccinated cats showed a rapid
increase following challenge.
In conclusion, the results from this study demonstrate that concurrent or simultaneous administration of
these twovaccines resulted in equivalent efﬁcacy; bothvaccine administration regimes showing signiﬁcant
differences in clinical scores or lower levels of persistent antigenaemia when compared to non-vaccinated
control cats following challenge.
 2013 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).IntroductionFeline leukaemia virus (FeLV) is a signiﬁcant pathogen of
domestic cats throughout the world [1]. Cats exposed to FeLV
may become either persistently viraemic or recover from the infec-
tion, with young cats being more rapidly infected following contact
exposure [2]. A third category of cats infected with FeLV are those
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cal infection and do not develop FeLV disease [3]. Those cats which
do recover from the infection produce virus neutralising antibodies
which are considered important in preventing re-infection and can
be passed through colostrum to protect neonatal kittens [4].
Feline calicivirus (FCV) is another highly infectious pathogen of
cats, with a widespread distribution in the cat population [5,6].
Studies have shown that the prevalence is broadly related to the
number of cats in a speciﬁc household or other location; with,
for example, privately owned animals present in small numbers
[7] having a lower prevalence than those kept in a cat shelter.
FCV has signiﬁcant genetic diversity with the potential to produce
multiple strains, and as a result the range of clinical signs following
infection can be broad, with the most common being oral ulcera-
tion, with ocular and nasal discharge and pneumonia also observed
[8]. The presence of antibodies, either as maternally-derived or in-
duced through active vaccination, has been demonstrated to play a
role in reducing or eliminating the clinical signs of a FCV challenge
[9], but does not prevent infection [10].
Feline herpesvirus (FHV) infection results in feline viral rhino-
tracheitis, an infection with a worldwide distribution. The virus
replicates in the mucosal tissues of the conjunctiva and upper
respiratory tract and can result in a latent state through infection
of neuronal tissue [11]. The presence of latent carrier cats can lead
to the infection of others through reactivation of the virus and
resultant shedding into the environment [12]. Lesions are a com-
mon result of mucosal infection with epithelial necrosis and im-
mune cell inﬁltration [13]; but other clinical signs observed in
cats include fever, depression, anorexia, ocular or nasal discharge,
and respiratory problems.
Feline panleukopenia virus (FPV) is deﬁned as the prototypical
carnivore parvovirus [14], and infection results in systemic disease
through cellular depletion within lymphoid tissues thus causing
immune suppression of the animal. The bone marrow is also im-
pacted with virus replicating in early progenitor cell lines thereby
affecting virtually all of the myeloid cell populations; this deﬁnes
the panleukopenia that is observed. Infection of kittens while in
the uterus or in the immediate period after birth can affect the cen-
tral nervous system leading to ataxia and tremors in the neonatal
animals. Signiﬁcant mortality is found in younger cats, although
the virus affects all age groups [15].
The severity of FCV, FHV and FPV infection is such that vaccines
to these agents are considered core feline vaccine requirements
[16], and are often produced as combination products. Vaccines
against FeLV are not considered core, but are often administered
at the same time as the core range. In this study we have evaluated
the efﬁcacy of each of four vaccine components when the core vac-
cine (Versifel CVR; FCV, FHV and FPV) was administered at the
same time as the FeLV vaccine (Versifel FeLV). The vaccines were
administered either concurrently (two separate vaccinations at dif-
ferent body locations) or simultaneously (single vaccination with
products mixed) with responses to virulent challenge being com-
pared to those of non-vaccinated control cats.Materials and methods
This study reports the results of four separate challenge studies
investigating the efﬁcacy of FeLV, FCV, FPV and FHV present in two
vaccines (Versifel FeLV and Versifel CVR) when administered to
cats aged 8–9 weeks old. The two vaccines were administered
either concurrently (2 injections at different body locations) or
simultaneously (vaccines mixed with single injection), with
responses compared to those of non-vaccinated animals. The stud-
ies were performed in accordance with the respective European
Pharmacopeia monographs: 01/2008:1321 (FeLV), 01/2008:1206(FHV), 01/2008:0251 (FPV) and 01/2008:1102 (FCV). The studies
were of 55 (FHV), 56 (FPV and FCV) or 147 (FeLV) days duration.
All studies were reviewed and approved by Zoetis institutional
animal use and care ethical review committees.
Animals
Cats aged 7–9 weeks of age, obtained from SPF breeding units
and conﬁrmed sero-negative to FeLV, FCV, FHV and FPV) ELISA or
virus neutralisation assay performed at commercial contract labo-
ratories) were used in each study. For the FeLV study 46 cats were
enrolled (12 non-vaccinated and 17 each for the concurrent and
simultaneous administration), 36 cats were enrolled on each of
the FHV and FCV studies (12 cats per treatment group), and 18 cats
were enrolled on the FPV study (6 cats per treatment group).
Vaccine
An experimental vaccine blend of Versifel FeLV (Zoetis) was
prepared in company formulation development laboratories, with
antigen input titre at the minimum release value as speciﬁed in
the EU authorisations. The Versifel CVR vaccine (Zoetis) was from
commercial stocks, with the potency of FCV, FHV or FPV viral anti-
gens at values within the normal production release titres. Water
for injection was administered to non-vaccinated animals.
On days 0 and 21, all animals in the non-vaccinated control
group received a subcutaneous injection at the interscapular space
at the base of the neck of 1 mL of sterile water for injection; ani-
mals in the concurrent administration group were vaccinated with
1 mL of Versifel FeLV subcutaneously at the interscapular space at
the base of the neck and subcutaneously with 1 mL of Versifel CVR,
reconstituted in sterile water, on the left thoracic wall behind the
elbow; and all animals in the simultaneous administration group
were vaccinated with 1 mL of Versifel CVR reconstituted in Versifel
FeLV subcutaneously at the interscapular space at the base of the
neck.
Challenge
The four studies used challenge viruses and dosing scheme as
follows. The FeLV Glasgow A strain was obtained from the Univer-
sity of Glasgow; 1 mL per cat was administered on days 42 and 45
by the oronasal route with a target dose of 6  105 ffu/mL. The
FHV-SGE strain was obtained from the USDA Animal and Plant
Health Inspection Service (APHIS); 1 mL containing 105.0 TCID50
per dose was administered oronasally to cats on day 42. The FPV
strain ICK-33 was obtained from APHIS; 1 mL containing 105.7
TCID50 per dose was administered by the intra-peritoneal route
to cats on day 42. The FCV strain FCC-255 was also obtained from
APHIS; 1 mL containing 106.8 TCID50 per dose was administered to
cats by the oronasal route on day 42.
Observations and samples
Table 1 shows the observations and samples collected in each
study with the day performed. Where clinical observations were
performed they included an assessment of depression, ocular or
nasal discharge, conjunctivitis, nasal and oral ulcers in addition
to general physical condition. Additional observations for ataxia
and tremors were conducted in the panleucopenia study.
Laboratory analysis
FeLV p27 antigen was measured using the SNAP FeLV system by
IDEXX according to the manufacturer’s protocols. FPV, FCV and
FHV antibody titres were detected using serum neutralisation
Table 1
Summary of observations and samples collected for each challenge study by day performed.
Observation or
sample
Day of study when observation or sample performed
FeLV FHV FPV FCV
Clinical
observation
1–14, 22–35, 43, 44, 46 and 47, then weekly
from day 63 to day 140
0 and 20a, 1 and 21b, 40 and 41c;
then on days 42–55
0 and 21a, 1 and 22b, then
on days 41–56
0 and 20a, 1 and 21b, 40 and
41c; then on days 42–55
Rectal or tympanic
temperatures
7, 1, 0a,b, 1–4, 20, 21a,b, 22–25, 42–46c,
then weekly from day 63 to day 147
8, 4 to 1, 0, 1, 20, 21, 40, 41c;
then days 42 to 55 inclusive
7, 1, 0, 1, 21, 22, 41, 42c;
then days 43 to 56
8, 3 to 1, 0a, 1, 21a, 22, 41,
42c; then 43–56
Blood samples 7, 21, 41 and 63, then weekly until day 147 2, 19, 40 and 55 Serology: 1, 20, 38 and 56
WBC: 34, 38, 46, 48, 50 and
52
1, 20, 41 and 56
FeLV, feline leukaemia virus; FHV, feline herpes virus; FPV, feline panleucopenia virus; FCV, feline calicivirus.
a Before vaccination.
b After vaccination.
c Before challenge.
Table 2
Animals positive for FeLV P27 antigen at each time point.
Study day a Non-vaccinated controls (1 mL water
for injection)
Concurrent administration (1 mL Versifel FeLV and
1 mL Versifel CVR)
Simultaneous administration (1 mL Versifel FeLV and
Versifel CVR mixed)
n Number (%) n Number (%) n Number (%)
Number (and percentage) of animals positive for FeLV p27-antigen
7 11 0 (0.0) 16 2 (12.5) 15 0 (0.0)
21 11 0 (0.0) 16 0 (0.0) 15 0 (0.0)
41 11 0 (0.0) 16 0 (0.0) 15 0 (0.0)
63 11 9 (81.8) 16 2 (12.5) 15 3 (20.0)
70 11 10 (90.9) 16 5 (31.3) 15 3 (20.0)
77 11 10 (90.9) 16 4 (25.0) 15 3 (20.0)
84 11 9 (81.8) 16 4 (25.0) 15 2 (13.3)
91 11 9 (81.8) 16 4 (25.0) 15 3 (20.0)
98 11 9 (81.8) 16 2 (12.5) 15 2 (13.3)
105 11 9 (81.8) 16 2 (12.5) 15 3 (20.0)
112 11 9 (81.8) 16 2 (12.5) 15 2 (13.3)
119 11 9 (81.8) 16 2 (12.5) 15 2 (13.3)
126 11 9 (81.8) 16 2 (12.5) 15 2 (13.3)
133 11 9 (81.8) 16 2 (12.5) 15 3 (20.0)
140 11 9 (81.8) 16 5 (31.3) 15 3 (20.0)
147 11 9 (81.8) 16 5 (31.3) 15 3 (20.0)
Number (and percentage) of animals with persistent antigenaemiab
11 10 (90.9) 16 4 (25.0) 15 3 (20.0)
a Cats were vaccinated on days 0 and 21, and challenged on days 42 and 45 with FeLV.
b Animals were considered to have a persistent p27 antigenaemia, where a positive result for the FeLV p27 antigen was observed at three consecutive weekly sampling
time points, or on at least ﬁve separate occasions during the study commencing 3 weeks after challenge.
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tion method in 96-well microtitre plates. After heat inactivation
at 56 C for 45 min, twofold serial dilutions of serum samples were
prepared. Each well of a microtitre plate was inoculated with
0.5 mL of neat or diluted serum from each dilution. To the 0.5 mL
volume of serum dilutions, a 0.5 mL aliquot of transport medium
containing 100–300 TCID50 of the challenge virus of interest was
added. Plates were incubated at 36 C for 1 hour. Following incuba-
tion, 0.2 mL of the serum/virus solution was added to each well of
quadruplicate microtitre plates containing cells. Inoculated plates
were incubated in an incubator for 5 days at 36 C. Wells were
examined for cytopathic effect and speciﬁc ﬂuorescent stain. SN
antibody titres were expressed as the reciprocal of the dilution that
neutralised 50% of the virus, as calculated by the method of Spear-
man–Karber (50% end-point method).
White blood cell counts were determined in Zoetis analytical
laboratories, Kalamazoo, with total and differential white blood
cell counts provided using an automated counter (ADVIA Haema-
tology System, Siemens).
The quantity of the virus in clariﬁed faecal swabs was deter-
mined as follows: samples were thawed in a cool water bath. After
samples were vortexed for 10–30 s, 300 ll was transferred to anEppendorf tube. The sample was centrifuged to pellet the swab
debris. Supernatant from this treatment was diluted in virus trans-
port media, starting at a 1:6 dilution, and with further 1:6 serial
dilutions of each processed sample. A positive control virus and a
negative cellular control were also prepared. The transport media
contained DMEM supplemented with 2 mM L-Glutamine, 1% anti-
biotic/antimycotic and (20 lL/mL) gentamicin solutions. An
aliquot of 0.2 mL of each dilution was inoculated into 4 replicate
wells. Inoculated plates were incubated in an incubator for 5 days
at 36 C. Wells were examined for cytopathic effects or ﬂuorescent
stain typical of viral infection. Viral titres were expressed as the re-
ciprocal of the dilution that neutralized 50% of the virus, as calcu-
lated by the method of Spearman–Karber (50% end-point method).
Statistical analysis
A biometrics representative of Zoetis was responsible for all
summaries of the data. The analyses described hereafter were
not all performed for each study.
FeLV p27 antigen status of each animal at each sampling point
was determined and the number and percentage of animals with a
positive result for FeLV p27 antigen was calculated according to
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mals with persistent p27 antigenaemia as deﬁned in the European
Pharmacopoeia Monograph 01/2008:1321 was calculated for each
treatment group.
Serological titres of antibodies (FHV, FPV or FCV in each study
with the respective challenge) detected were presented with
descriptive statistics. These included the geometric mean, mini-
mum and maximum titre for each treatment group and each time
point where applicable.
Where white blood cell counts were obtained these were sum-
marised for all animals. An arithmetic mean of leukocyte count
was calculated for each treatment group by study day. For each
kitten the initial baseline value for total cells as well as differential
lymphocyte or neutrophils was calculated and the percentage
reduction (including the mean, standard deviation, minimum and
maximum) from this value was calculated for each post-challenge
time point. The number of cats that experienced at least a 50% or
75% reduction from baseline at any time point was summarised
by treatment group.
Clinical scores for the FHV and FCV studies were calculated
according to the system deﬁned in the European Pharmacopeia
monographs, with the clinical score for each animal calculated as
the total sum of all the scores for each day assessed, plus the scores
for the clinical signs that are only assessed once (death, weight
loss, number of days of virus excretion). The rank of the clinical
scores were analysed using a general linear mixed model. Con-
trasts were used to compare the concurrent administration or
simultaneous administration groups to the non-vaccinated group.
The median, minimum and maximum score was calculated for
each treatment group. Mean baseline tympanic or rectal tempera-
tures were calculated and summarised by treatment group from
tympanic temperature data recorded prior to vaccination. In
addition tympanic or rectal temperatures were summarised by
treatment group for the vaccination phase and also for the post-
challenge phase. This included the mean, standard deviation, min-
imum and maximum.
Results
Feline leukaemia virus challenge
Forty-two out of the 46 animals enrolled completed the study;
one animal was withdrawn from the study prior to secondFig. 1. Geometric mean FHV-SGE antibody titres for animals in each treatment group a
simultaneously, or sterile water on day 0 and 21, and were challenged with FHV on d
administration.vaccination (day 21), two animals were euthanased prior to study
completion (on days 73 and 76 respectively) and one further ani-
mal died prior to study completion (day 91).
Throughout the study various abnormal health observations
were recorded and for the three treatment groups most signs were
mild and required minimal intervention, if any. The predominant
signs observed prior to challenge occasionally included enlarged
lymph nodes and small transient injection site reactions. There
was little apparent difference in rectal temperature between the
three treatment groups throughout the study, but following chal-
lenge the animals in the concurrent or simultaneous administra-
tion groups had mean rectal temperatures higher than those in
the non-vaccinated group.
None of the 46 cats which participated in the study were posi-
tive for FeLV p27 antigen prior to administration of the FeLV chal-
lenge. The number and percentage of animals positive for the FeLV
p27 antigen at each time point together with the total number and
percentage of animals in each treatment group with persistent p27
antigenaemia are summarised in Table 2. In the non-vaccinated
group ten of the 11 animals (91%) met the criteria for persistent
p27 antigenaemia; while of the 17 animals enrolled in the concur-
rent administration group, 16 cats completed the study and four (4
of 16, 25%) met the criteria for persistent p27 antigenaemia. Three
of the 17 animals enrolled in the simultaneous administration
group, of which 15 completed the study, were considered to have
p27 antigenaemia (3 of 15, 20%).
Feline rhinotracheitis (herpes) virus
Thirty-ﬁve out of the 36 kittens enrolled in the study completed
the study. In the period post challenge one animal died on day 52
as a result of enteritis caused by an ileal stenosis, unrelated to FHV
disease.
Following challenge various clinical signs of FHV infection were
recorded, and included depression, nasal and ocular discharge,
coughing or sneezing, conjunctivitis and weight loss. Clinical signs
of abnormal health observations were observed less frequently in
the simultaneous administration group than in the concurrent
administration and non-vaccinated groups. The median of the rank
of clinical scores was 29.3 in the non-vaccinated group, 17.5 in the
concurrent administration group and lowest 10.5 for the simulta-
neous administration group. There was a signiﬁcant difference in
clinical scores between non-vaccinated control and concurrentt each time point. Animals received either a FeLV and CVR vaccine concurrently or
ay 42. NV, non-vaccinated; Conc, concurrent administration; Simul, simultaneous
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control and simultaneous administration groups (P < 0.0001). In
all treatment groups, tympanic temperatures remained in the
range 37.6–39.4 C throughout the study except for day 45 (4 days
post challenge) where four animals in the non-vaccinated group
had elevated temperatures (39.5–39.8 C).
The geometric mean FHV-SGE antibody titres for animals in
each treatment group at each time point are shown in Fig. 1. All
cats remained sero-negative until after the second vaccination,
the control cats remaining sero-negative until after challenge
(mean titre 20.3). Cats administered vaccines concurrently showed
a slight increase in mean titres after second vaccination (mean titre
1.4) and all cats sero-converted after challenge (mean titre 54.3).
The cats administered vaccines simultaneously also showed
increases after second vaccination (mean titre 4.9) with further in-
creases in antibody titre after challenge (mean titre 77.6).
Feline panleucopenia virus
All enrolled cats completed the study, and there were no re-
ported incidences of depression, anorexia, vomiting, diarrhoea,Table 3
White blood cell counts, percent reduction from baseline for each treatment group by ind
Treatment Baseline (103 cells/lL) Day 46 (%) Day 4
Non-vaccinated 16.27 71.0 54.4
14.63 40.3 84.1
14.12 76.7 74.2
16.73 79.9 72.5
10.68 64.5 76.8
15.28 79.2 82.7
Concurrent administration 22.61 17.1 28.2
12.42 22.1 19.6
11.94 1.3 9.4
10.55 29.7 11.8
11.75 8.5 3.6
17.17 23.7 7.4
Simultaneous administration 16.23 2.9 17.2
13.50 24.3 18.4
19.73 29.9 16.2
20.03 5.8 27.4
15.87 14.6 16.8
12.59 5.4 23.9
Fig. 2. Geometric mean FPV antibody titres for animals in each treatment group at e
simultaneously, or sterile water on day 0 and 21, and were challenged with FPV on d
administration.dehydration, ataxia, tremor, or agitation following handling in
any of the treatment groups. All temperatures were within the nor-
mal range throughout the study.
All kittens in the non-vaccinated group showed a 50%, or great-
er, reduction in leucocytes (WBC) from the baseline value on at
least one occasion post challenge and all but one kitten showed a
75%, or greater, WBC count reduction from the baseline values on
at least one occasion. In contrast, no reductions in WBC count
greater than 50% from baseline were observed in any of the cats
in either the concurrent administration or simultaneous adminis-
tration groups (Table 3).
When examining the differential lymphocyte counts, all cats in
the non-vaccinated group showed a 75% or greater reduction in
lymphocyte count and monocyte count on at least one occasion
following challenge. All cats in the non-vaccinated group also
showed at least a 50% reduction in neutrophils on at least one oc-
casion post challenge; 4 of the 6 cats showed a reduction greater
than 75% from baseline. None of the cats in the simultaneous
administration group showed signiﬁcant reductions in their lym-
phocyte, neutrophil or monocyte counts on any occasion post chal-
lenge. In the concurrent administration group, none of the catsividual animal following feline panleucopenia challenge.
8 (%) Day 50 (%) Day 52 (%) >50% Reduction >75% Reduction
66.0 72.3 Yes No
76.3 56.4 Yes Yes
77.3 67.6 Yes Yes
60.5 45.1 Yes Yes
35.1 78.1 Yes Yes
53.5 41.9 Yes Yes
25.9 26.6 No No
27.4 36.4 No No
0.4 9.2 No No
3.3 14.3 No No
18.2 11.9 No No
24.1 20.4 No No
0.6 4.5 No No
29.1 40.6 No No
23.3 9.9 No No
21.3 21.6 No No
-4.5 11.3 No No
6.8 8.5 No No
ach time point. Animals received either a FeLV and CVR vaccine concurrently or
ay 42. NV, non-vaccinated; Conc, concurrent administration; Simul, simultaneous
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challenge, but 2 cats showed a 50%, or greater, reduction of their
neutrophil counts post challenge and 1 cat showed a 50%, or great-
er, reduction in their monocyte count post challenge.
All cats in the concurrentandsimultaneousadministrationgroups
increased their antibody levels to FPV from <2 toP5793 by day 20
andmaintained the samehigh level of antibodies though day 56with
the exceptionof one animal. Control cats in thenon-vaccinatedgroup
showed the same increase in antibody levels after challenge (on day
56). The geometric mean FPV antibody titres for animals in each
treatment group at each time point are shown in Fig. 2.Feline calicivirus
All enrolled cats completed the study. Post challenge, tympanic
temperatures were normal (37.1–39.4 C) in all treatment groups.
Slight increases in tympanic temperature were observed in indi-
viduals in the non-vaccinated group post-challenge, between study
days 43 and 47, but these still remained within the normal range.
Of the clinical data collected from day 41 onwards, non-vacci-
nated cats had the highest incidence of ulcers (nasal and/or oral),
with 10 of 12 animals (83.3%) having ulcers compared to two of
12 (16.7%) animals in the concurrent administration group and
three of 12 (25.0%) animals in the simultaneous administration
group. Non-vaccinated cats also experienced a higher incidence
(4 of 12 cats; 33%) of nasal discharge, while one animal in the con-
current administration group experienced slight nasal discharge.
The median of the rank of clinical scores was the highest, at 30.5,
in the non-vaccinated group (ranging between 12.5 and 36.0)
and at 12.5 for both the concurrent and simultaneous administra-
tion groups (ranging between 2.5 and 27.0 and 28.0 respectively).
There was a statistically signiﬁcant difference (P < 0.0001) between
non-vaccinated and concurrent administration groups for the anal-
ysis of ranks of clinical scores, as well as between non-vaccinated
and simultaneous administration groups (P < 0.0001).
The geometric mean FCV antibody titres for animals in each
treatment group at each time point are shown in Fig. 3.Discussion
In this paper we have evaluated the protective efﬁcacy follow-
ing virulent challenge with FeLV, FCV, FHV or FPV of the vaccineFig. 3. Geometric mean FCV antibody titres for animals in each treatment group at e
simultaneously, or sterile water on day 0 and 21, and were challenged with FCV on d
administration.combination when administered concurrently or simultaneously
to cats of 9 weeks of age. Other studies have demonstrated that
mixing multiple antigens within vaccine formulations can reduce
their respective efﬁcacy against challenge [17]. It was therefore
important to demonstrate that the efﬁcacy of each vaccine compo-
nent is not impacted when the two products are administered to
cats at the same time, and further, that mixing the vaccines and
administering them simultaneously also has no impact on protec-
tive efﬁcacy.
In the current investigation, all control cats were observed with
clinical signs of infection or persistent antigenaemia following
challenge with FCV, FHV, FPV or FeLV; these observations were
consistent with previous investigations [9,11,14,18]. The four stud-
ies performed demonstrated that vaccination with the combina-
tion of two vaccines was efﬁcacious with reductions in persistent
antigenaemia (FeLV) or reduced incidence of clinical signs, lower
reductions in white blood cell counts, but elevated antibody re-
sponses (FCV, FHV and FPV). Although there was some variability
in antibody responses between cats administered the two vaccines
concurrently versus those administered simultaneously, especially
with the FCV study, these are not thought to be clinically signiﬁ-
cant as vaccinated cats were protected following challenge. The
role of antibodies in protection against clinical symptoms of dis-
ease or infection by FCV [19], FPV [14] and FHV [11] has been dem-
onstrated, although for the FCV and FHV viruses this response is
not as robust as mild signs of clinical disease have also been ob-
served. In the current study we also observed small numbers of
vaccinated cats with mild clinical signs following challenge infec-
tion with virulent heterologous viruses. It should be noted how-
ever that these studies used a challenge virus titre which is likely
to be much greater than would be encountered in ﬁeld conditions,
and vaccinated cats would show low or no clinical signs with a
lower environmental exposure to FCV or FHV.
The efﬁcacy of vaccines to FeLV, or FCV, FHV and FPV, when
administered separately has been well established. Although vacci-
nation against FeLV has been demonstrated [20] to have variable
product and efﬁcacy claims, considerable protection has been suc-
cessfully demonstrated in laboratory [18,21] studies following vir-
ulent challenge as well as under ﬁeld conditions [22]. Similarly, the
efﬁcacy of trivalent vaccines (FCV, FHV and FPV) have been evalu-
ated in laboratory [23] and ﬁeld conditions [24]. There have been
limited studies examining the co-administration of a FeLV vaccine
together with one to FCV, FHV and FPV [25]; but in that particularach time point. Animals received either a FeLV and CVR vaccine concurrently or
ay 42. NV, non-vaccinated; Conc, concurrent administration; Simul, simultaneous
32 S. Wilson et al. / Trials in Vaccinology 3 (2014) 26–32study the authors did not examine efﬁcacy following virulent chal-
lenge. However, they did demonstrate that co-administration of
the two vaccines, one of which was adjuvanted, led to an enhanced
immune response to the components of the non-adjuvanted vac-
cine. A treatment group comprising only the trivalent vaccine
administration was not included in our current study, so we cannot
determine whether an enhanced immune response was observed
in the co-administered groups.
As with the study by Brunner and others [25], either no, or very
mild, abnormal local or systemic reactions were observed, and no
abnormal rectal temperature measurements were recorded during
the vaccination phase prior to each respective challenge; indicating
that co-administration of the two vaccines is safe. Only during the
FeLV study were mild local injection site reactions detected follow-
ing vaccination; these were comparable to observations seen when
the FeLV vaccine was administered as a single product [22]. These
reactions were of no clinical relevance and quickly resolved with-
out any additional treatment being required.
In conclusion, the results from this study demonstrate that the
use of the multi-valent vaccine, containing FCV, FHV and FPV, in
combination with an adjuvanted FeLV vaccine following concur-
rent or simultaneous administration resulted in no decrease in efﬁ-
cacy, as has been shown with other vaccine combinations [17];
both administration regimes showed signiﬁcant differences in
clinical scores or lower levels of persistent antigenaemia when
compared to non-vaccinated control cats following challenge.References
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